Rifabutin: a repurposed antibiotic with high potential against planktonic and biofilm staphylococcal clinical isolates
Frontiers in Microbiology · 10.10.2024 · 15
DOI: 10.3389/fmicb.2024.1475124 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Microbiology, online erschienen am 10.10.2024. Verfasst von Magda Ferreira und 5 weiteren Autor:innen. Beteiligte Einrichtung: Center for Interdisciplinary Research in Animal Health (CIISA), Faculty of Veterinary Medicine, Universidade de Lisboa, Lisbon, Portugal. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Staphylococcus aureus poses a significant threat as an opportunistic pathogen in humans, and animal medicine, particularly in the context of hospital-acquired infections (HAIs). Effective treatment is a significant challenge, contributing substantially to the global health burden. While antibiotic therapy remains the primary approach for staphylococcal infections, its efficacy is often compromised by the emergence of resistant strains and biofilm formation. The anticipated solution is the discovery and development of new antibacterial agents. However, this is a time consuming and expensive process with limited success rates. One potential alternative for addressing this challenge is the repurposing of existing antibiotics. This study investigated the potential of rifabutin (RFB) as a repurposed antibiotic for treating S. aureus infections. The minimum inhibitory concentration (MIC) of rifabutin was assessed by the broth microdilution method, in parallel to vancomycin, against 114 clinical isolates in planktonic form. The minimum biofilm inhibitory concentration (MBIC 50 ) was determined by an adaptation of the broth microdilution method, followed by MTT assay, against a subset of selected 40 clinical isolates organized in biofilms. The study demonstrated that RFB MIC ranged from 0.002 to 6.250 μg/mL with a MIC 50 of 0.013 μg/mL. RFB also demonstrated high anti-biofilm activity in the subset of 40 clinical isolates, with confirmed biofilm formation, with no significant MBIC 50 differences observed between the MSSA and MRSA strains, in contrast to that observed for the VAN. These results highlight the promising efficacy of RFB against staphylococcal clinical isolates with different resistance patterns, whether in planktonic and biofilm forms.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Interdisciplinary Research in Animal Health (CIISA), Faculty of Veterinary Medicine, Universidade de Lisboa, Lisbon, Portugal.
- Associate Laboratory for Animal and Veterinary Sciences (AL4AnimalS), Lisbon, Portugal.
- Faculty of Pharmacy, Research Institute for Medicines (iMed.ULisboa), Universidade de Lisboa, Lisbon, Portugal.
- Laboratório de Microbiologia do Serviço de Patologia Clínica do Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal.
- Faculty of Sciences, Institute of Biophysics and Biomedical Engineering (IBEB), Universidade de Lisboa, Lisbon, Portugal.
Zitieren
APA
Ferreira, M., Pinto, M., Aires-da-Silva, F., Bettencourt, A., Gaspar, M. M., & Aguiar, S. I. (2024). Rifabutin: a repurposed antibiotic with high potential against planktonic and biofilm staphylococcal clinical isolates. Frontiers in Microbiology, 15. https://doi.org/10.3389/fmicb.2024.1475124
Vancouver
Ferreira M, Pinto M, Aires-da-Silva F, Bettencourt A, Gaspar MM, Aguiar SI. Rifabutin: a repurposed antibiotic with high potential against planktonic and biofilm staphylococcal clinical isolates. Frontiers in Microbiology. 2024;15. doi:10.3389/fmicb.2024.1475124
BibTeX
@article{Ferreira2024,
author = {Ferreira, Magda and Pinto, Margarida and Aires-da-Silva, Frederico and Bettencourt, Ana and Gaspar, Maria Manuela and Aguiar, Sandra Isabel},
title = {Rifabutin: a repurposed antibiotic with high potential against planktonic and biofilm staphylococcal clinical isolates},
journal = {Frontiers in Microbiology},
year = {2024},
volume = {15},
doi = {10.3389/fmicb.2024.1475124}
}
EUVIMED